Novo Nordisk Pushes Portfolio and Culture Reset Ahead of London Capital Markets Day

Novo Nordisk gains EU panel backing for Sogroya and FREHEMGO, signs an Orbis licensing deal worth up to $1.4 billion, and rebrands as "Novo" under CEO Mike Doustdar.

A pair of regulatory wins in Brussels, a billion-dollar licensing gamble and an internal rebrand are converging on Novo Nordisk this week, setting the stage for a capital markets day in London next Monday where management will lay out its revised strategy to investors.

The Danish drugmaker received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday for its once-weekly growth hormone Sogroya (somapacitan), cleared for treating children with idiopathic short stature and persistent growth impairment. Should the European Commission follow the recommendation later this year, Sogroya would become the first and only therapy specifically approved for this indication across the EU.

That endorsement landed barely a day after the same panel backed FREHEMGO (denecimig) for hemophilia A in adults and children. The compound is the first FVIIIa mimetic to offer prophylaxis via a ready-to-use pen at intervals of once weekly, every two weeks or once monthly. Supporting data from the Phase 3b FRONTIER5 study, published Thursday in the Journal of Thrombosis and Haemostasis, showed favorable tolerability when patients switched directly from emicizumab to denecimig, alongside sustained thrombin generation within the normal range. Novo Nordisk intends to launch FREHEMGO in the first European markets during the fourth quarter of 2026, widening the rollout across the EU from early 2027.

Orbis Deal Adds Oral Pipeline

On the research front, the company signed a licensing and development agreement with Orbis Medicines on Thursday, a deal Reuters reported could reach a total volume of up to $1.4 billion. The partnership centers on oral therapies and includes a strategic investment by Novo Nordisk in its new collaborator, reinforcing the group's cardiometabolic pipeline.

Technology is another lever being pulled. Novo Nordisk disclosed a collaboration with Anthropic on Wednesday aimed at tackling drug discovery challenges through artificial intelligence, streamlining scientific workflows and accelerating the development of new medicines.

Culture Shift Under CEO Mike Doustdar

Running alongside these external moves is a push to reshape the company from within. CEO Mike Doustdar urged staff on Tuesday to build a more customer-focused culture, according to Reuters, as the group looks to recover ground lost in the fiercely competitive obesity treatment market. The effort follows Monday's introduction of a framework called "The Novo Way," built around customer focus, competitiveness, clarity and integrity. As part of the shift, the company will use the shortened name "Novo" in day-to-day operations while keeping its legal name, Novo Nordisk A/S, unchanged. A fresh brand identity under the tagline "Lasting Health Starts Now" was also unveiled on Monday.

Not every pipeline project has gone to plan. Earlier this month, Novo Nordisk halted two clinical trials of ziltivekimab in heart failure patients after an independent data monitoring committee found a low probability that results would differ from a previously failed study.

Attention now turns to scientific disclosures. The company said it will present clinical and real-world data at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan from September 28 to October 2, covering findings on the Wegovy pill and next-generation amylin compounds.

In Friday's subdued session, the stock closed at EUR 37.58, a modest daily decline of 0.3%. Since the start of the year, the shares have shed 15%, leaving them roughly 31% below their 52-week high of EUR 54.86 set in January. The Milan presentations should offer a clearer read on how durable the clinical outlook is for the company's next wave of hoped-for growth drivers.